Stephanie Bryant, DO
Family Medicine · Hobart, INNPI 1356577670
Payments from drug & device makers
Across 260 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$685
- Novo Nordisk$419
- Pfizer$367
- Merck$237
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$223
- GSK$218
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,880100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $685 |
| Novo Nordisk | 31 | $419 |
| Pfizer | 36 | $367 |
| Merck | 23 | $237 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $223 |
| GSK | 15 | $218 |
| AstraZeneca | 15 | $203 |
| Lilly USA, LLC | 11 | $180 |
| Dexcom, Inc. | 4 | $105 |
| Sanofi-aventis U.S. LLC | 7 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $100 |
| Johnson & Johnson | 5 | $91 |
| Boehringer Ingelheim | 5 | $81 |
| Xeris Pharmaceuticals, Inc. | 4 | $77 |
| Amgen | 4 | $74 |
| Ironwood Pharmaceuticals, Inc | 5 | $70 |
| Astellas Pharma US Inc | 4 | $70 |
| Eisai Inc. | 4 | $70 |
| Otsuka America Pharmaceutical, Inc. | 4 | $65 |
| Sanofi Pasteur Inc. | 4 | $62 |
| Abbott | 2 | $40 |
| Mylan Specialty L.p. | 2 | $34 |
| Lundbeck LLC | 1 | $30 |
| Bayer | 1 | $30 |
| Exact Sciences | 1 | $23 |
| Insulet Corporation | 1 | $21 |
| Exeltis, USA Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Tris Pharma Inc | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Duchesnay USA Incorporated | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $12 |
| Biodelivery Sciences International, Inc. | 1 | $11 |
How this compares
$3,880 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $129,788 |
| JardianceEmpagliflozin | 35 | $52,444 |
| XifaxanRifaximin | 12 | $40,345 |
| TrulicityDulaglutide | 27 | $40,206 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $32,208 |
| MounjaroTirzepatide | 13 | $27,165 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $26,187 |
| EliquisApixaban | 15 | $21,708 |
| XareltoRivaroxaban | 18 | $20,802 |
| JanuviaSitagliptin Phosphate | 11 | $17,465 |
| FarxigaDapagliflozin Propanediol | 14 | $15,721 |
| UbrelvyUbrogepant | 11 | $11,871 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $10,447 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $9,844 |
| Levemir FlexpenInsulin Detemir | 13 | $5,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $419 | $131,003119 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $180 | $67,37140 claims |
| Boehringer IngelheimJardiance | $81 | $52,44435 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $218 | $42,65552 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $223 | $40,34512 claims |
| PfizerEliquis | $367 | $21,70815 claims |
| Johnson & JohnsonXarelto | $91 | $20,80218 claims |
| MerckJanuvia | $237 | $17,46511 claims |
| AstraZenecaFarxiga | $203 | $15,72114 claims |
| AbbVieUbrelvy, Synthroid, Armour Thyroid | $685 | $14,31552 claims |
| Sanofi-aventis U.S. LLCLantus | $101 | $68411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Hobart
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.